Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
VTYX 
Ventyx Biosciences Inc (VTYX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: VTYX (3-star) is a REGULAR-BUY. BUY since 48 days. Simulated Profits (180.39%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.14
1 Year Target Price $15.14
| 5 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -8.48% | Avg. Invested days 22 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 622.25M USD | Price to earnings Ratio - | 1Y Target Price 15.14 |
Price to earnings Ratio - | 1Y Target Price 15.14 | ||
Volume (30-day avg) 9 | Beta 1.23 | 52 Weeks Range 0.78 - 10.55 | Updated Date 12/6/2025 |
52 Weeks Range 0.78 - 10.55 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.49 |
Earnings Date
Report Date 2025-11-07 | When - | Estimate -0.45 | Actual -0.32 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.47% | Return on Equity (TTM) -45.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 376837721 | Price to Sales(TTM) - |
Enterprise Value 376837721 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -22.93 | Shares Outstanding 71358638 | Shares Floating 60108235 |
Shares Outstanding 71358638 | Shares Floating 60108235 | ||
Percent Insiders 4.11 | Percent Institutions 68.38 |
Upturn AI SWOT
Ventyx Biosciences Inc
Company Overview
History and Background
Ventyx Biosciences Inc. was founded in 2018. The company is focused on developing novel therapies for inflammatory diseases. A significant milestone was its initial public offering (IPO) in 2021, which provided capital for clinical development. The company has evolved from a preclinical-stage biopharmaceutical company to one actively engaged in clinical trials.
Core Business Areas
- Inflammatory Disease Therapeutics: Ventyx Biosciences Inc. is dedicated to the discovery and development of small molecule inhibitors targeting key inflammatory pathways implicated in a range of immune-mediated diseases. Their pipeline primarily focuses on conditions such as psoriasis, inflammatory bowel disease (IBD), and other autoimmune disorders.
Leadership and Structure
Ventyx Biosciences Inc. is led by a management team with extensive experience in drug development and the biopharmaceutical industry. The organizational structure is typical for a clinical-stage biopharmaceutical company, emphasizing research and development, clinical operations, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Vtx901 (JAK inhibitor): Vtx901 is a selective tyrosine kinase 2 (TYK2) inhibitor in clinical development for moderate to severe plaque psoriasis. Competitors in the JAK inhibitor space include companies with approved therapies like Pfizer (Xeljanz), AbbVie (Rinvoq), and Eli Lilly (Olumiant). The market share for TYK2 inhibitors is emerging, with Ventyx aiming to capture a segment of the large psoriasis market. Specific market share data for Vtx901 is not yet available as it is in clinical development.
- Vtx002 (S1P receptor modulator): Vtx002 is an orally administered sphingosine-1-phosphate (S1P) receptor modulator being developed for inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Competitors in the S1P modulator market include Bristol Myers Squibb (Zeposia) and others developing similar mechanisms. Market share for this specific drug is not yet established.
- Vtx1002 (ROCK inhibitor): Vtx1002 is a Rho-associated protein kinase (ROCK) inhibitor investigated for various inflammatory conditions. This is an earlier-stage program within Ventyx's pipeline, and market share is not applicable at this stage.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the segment focused on inflammatory and autoimmune diseases, is characterized by significant unmet medical needs and substantial market opportunities. It is driven by scientific innovation, rigorous regulatory processes, and intense competition. The market is growing due to an aging population and increasing prevalence of chronic inflammatory conditions.
Positioning
Ventyx Biosciences Inc. is positioned as a clinical-stage biopharmaceutical company aiming to address significant unmet needs in inflammatory diseases through the development of novel, selective small molecule therapies. Their competitive advantages lie in their differentiated drug candidates targeting specific pathways, potentially offering improved efficacy and safety profiles compared to existing treatments. However, as a clinical-stage company, they face the inherent risks of drug development and competition from established players.
Total Addressable Market (TAM)
The Total Addressable Market for inflammatory and autoimmune diseases is in the tens of billions of dollars globally and is projected to continue growing. Ventyx Biosciences Inc. is positioned to address a significant portion of this TAM with its pipeline of therapies targeting major indications like psoriasis and IBD. Their success will depend on the efficacy, safety, and market adoption of their lead candidates within these large markets.
Upturn SWOT Analysis
Strengths
- Targeted therapies with potentially improved safety and efficacy profiles.
- Experienced management team with a track record in drug development.
- Active clinical development programs in significant disease areas.
- Access to capital through IPO and potential future funding rounds.
Weaknesses
- Clinical-stage company with no approved products yet.
- High dependence on the success of a limited number of drug candidates.
- Significant capital requirements for ongoing clinical trials.
- Reliance on external partnerships for certain aspects of development or commercialization.
Opportunities
- Addressing unmet needs in large and growing markets for inflammatory diseases.
- Potential for strategic partnerships or acquisition by larger pharmaceutical companies.
- Advancements in understanding of disease pathways leading to new therapeutic targets.
- Expansion of pipeline into other inflammatory or autoimmune conditions.
Threats
- Clinical trial failures or delays.
- Intense competition from established pharmaceutical companies and other biotechs.
- Regulatory hurdles and lengthy approval processes.
- Pricing pressures and reimbursement challenges.
- Patent expirations of competitor drugs leading to increased competition.
Competitors and Market Share
Key Competitors
- AbbVie Inc. (ABBV)
- Bristol Myers Squibb Company (BMY)
- Eli Lilly and Company (LLY)
- Pfizer Inc. (PFE)
Competitive Landscape
Ventyx Biosciences Inc. faces a highly competitive landscape dominated by large pharmaceutical companies with established portfolios, extensive R&D capabilities, and significant commercial infrastructure. Ventyx's advantage lies in its potential to bring differentiated, more targeted therapies to market. However, it lags behind in terms of market presence, brand recognition, and existing revenue streams. Its ability to compete hinges on demonstrating superior clinical profiles for its pipeline drugs.
Growth Trajectory and Initiatives
Historical Growth: Ventyx Biosciences Inc.'s growth trajectory since its IPO has been focused on advancing its pipeline through key clinical milestones. This includes initiating and progressing Phase 1, 2, and potentially Phase 3 clinical trials for its lead drug candidates. The company's 'growth' is measured by the progress of its drug development and the expansion of its R&D capabilities.
Future Projections: Future projections for Ventyx Biosciences Inc. are heavily dependent on the successful outcomes of its ongoing clinical trials and the subsequent regulatory approvals. Analyst estimates would focus on potential peak sales of its lead products, timelines for regulatory submissions, and the overall market potential of its therapeutic areas. Forecasts will likely show increasing R&D investment followed by potential revenue generation post-commercialization.
Recent Initiatives: Recent initiatives for Ventyx Biosciences Inc. have likely included the progression of their drug candidates into later-stage clinical trials, expansion of their scientific advisory board, and strategic partnerships or collaborations to accelerate drug development or manufacturing.
Summary
Ventyx Biosciences Inc. is a promising clinical-stage biopharmaceutical company focused on inflammatory diseases. Its strengths lie in its targeted therapeutic approach and experienced team. However, it faces significant risks inherent in drug development, including clinical trial failures and intense competition. Key opportunities exist in large, unmet medical needs, but the company must navigate regulatory hurdles and secure substantial funding to bring its therapies to market. Monitoring clinical trial progress and competitive developments will be crucial.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Financial News Outlets (e.g., Bloomberg, Reuters)
- Biopharmaceutical Industry Analyst Reports
- Company Investor Relations Website
Disclaimers:
This JSON output is generated based on publicly available information and AI analysis. It is not a substitute for professional financial or investment advice. Investors should conduct their own due diligence before making any investment decisions. Market share data for clinical-stage companies is estimated and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ventyx Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-10-21 | Founder, CEO, President & Director Dr. Raju S. Mohan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 83 | Website https://ventyxbio.com |
Full time employees 83 | Website https://ventyxbio.com | ||
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.